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resolution of signs/symptoms, and survival. Financial
data were collected for the time of hospitalization.
RESULTS: Eleven patients have been enrolled. The
average age of the patients is 57 years (range 40–80). The
majority (64%) of the patients were female and 55% of
the patients had lymphoma. The infection was microbio-
logically documented in 27%, clinically documented in
46%, and twenty-seven percent of patients had a fever 
of unknown origin. The average length of hospitaliza-
tion was 9 days (range 3–27). One patient had an adverse
event due to an anti-infective and included chills and
rigors with amphotericin-B lipid complex. The average
number of febrile days was 3 (range 1–8). Every patient
except one had resolution of signs and symptoms of 
the infection. One patient died due to a viral pneumonia.
The anti-infective utilized most frequently was imipenem/
cilastatin. The average cost of hospitalization per patient
was $22,438 (range $5,222.60–$53,398.95). The average
cost of pharmaceuticals per patient was $6,947.50 (range
$2,929.81–$18,642.82).
CONCLUSIONS: Infectious complications in cancer
patients can produce morbidity and mortality as well 
as be costly. Infectious disease outcomes can easily be 
collected utilizing a Palm handheld.
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OBJECTIVES: Gemcitabine/Cisplatin (Gem/Cis) is a
standard regime commonly used in the treatment of 
non-small cell lung cancer. This study uses currently 
available clinical trial data to evaluate the cost implica-
tions of Gem/Cis versus other combination regimes in
Germany.
METHODS: Two published randomised controlled clin-
ical trials were used for this retrospective cost analysis to
evaluate and compare the cost of platinum-based combi-
nation regimes. Comella et al. (2000) compared, among
others, Gem/Cis versus Vinorelbine/Cisplatin (Vin/Cis)
and Schiller et al. (2000) compares Gem/Cis with 
Paclitaxel/Cisplatin (Pac/Cis), Paclitaxel/Carboplatin
(Pac/Carbo) and Docetaxel/Cisplatin (Doc/Cis). Equal
efﬁcacy was assumed for the analysis. Resource use and
unit costs associated with both treatment and toxicity
management were collected from the perspective of a
German sickness fund. Only direct cost (acquisition 
and administration of chemotherapy, hospitalisation and
other medical resource use) were considered.
RESULTS: Based on the Comella et al. (2000) clinical
trial, Gem/Cis was associated with lower overall costs
compared to Vin/Cis (€7638 vs. €8143). The higher
acquisition cost of Gem/Cis was more than compensated
by lower drug administration cost (€798 vs. €1278) and
fewer adverse events resulting in fewer hospitalisations
(€1633 vs. €2680). Based on the Schiller et al. (2000),
Gem/Cis was associated with the lowest overall costs 
of all ﬁrst-line treatment arms, Pac/Carbo and Pac/Cis
(€8.418 vs. €12.268 and €11.050). Even though the drug
acquisition cost of Gem/Cis was lower than Doc/Cis,
higher administration cost lead to slightly higher total
cost of Gem/Cis compared to Doc/Cis (€8418 vs. €8331).
CONCLUSIONS: From the perspective of German 
sickness funds, Gem/Cis as ﬁrst line treatment offers cost
advantages over Pac/Cis and Pac/Carbo in the treatment
of non-small cell lung cancer. Further research is 
necessary to validate these ﬁndings in a setting outside of
clinical trials.
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OBJECTIVES: Data on costs of care and typical care
paths for patients with malignant lymphomas in Germany
are scarce. The aims of this prospective health economic
survey are to identify typical clinical pathways and assess
the costs and clinical beneﬁts of different treatment 
settings and modalities for patients with newly diagnosed
malignant lymphomas.
METHODS: The recruitment of patients for this project
started in 2000 and will be continued through 2003 in
the Cologne and Saarland regions, Germany. Data on
resource consumption and outcomes are collected
prospectively by means of a patient book and a health
economic questionnaire. For the cohort of the one-year
pilot phase, hospital costs and costs of chemotherapy 
for the ﬁrst 6 months since initial diagnosis were 
calculated.
RESULTS: 192 patients have been recruited during 
the pilot phase. Of these, 22 (11,5%) were diagnosed
with Hodgkin’s disease (HD), 111 (57,8%) with non-
Hodgkin’s lymphoma (NHL), 36 (18,8%) with chronic
lymphatic leukemia (CLL) and 18 (9,4%) with multiple
myeloma (MM) (5 = 2,6% undeﬁned). The treatment
setting was as follows: 72 (43,6%) of the patients were
treated in an outpatient setting, 37 (22,4%) in an 
inpatient setting and 56 (33,9%) in a combined inpatient 
and outpatient setting. 54 (33,5%) patients were treated
